Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45
Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.
Read original at benzingaStocks · News reference
8-K filing — IMMUNIC, INC. (IMUX)
Filed: 2026-08-11 AccNo: 0001193805-26-001071 Size: 381 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 11, 2026, 11:05 AM
- Checked
- Aug 11, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same
Read original at benzinga